AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31018832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifamurtide
Number of subjects: 0
Study 31018832 — intervention group
Group type: COMPARATOR
Intervention: Historical individual control data
Number of subjects: 0
Study 31018832 — intervention group
Group type: COMPARATOR
Intervention: Aggregate treatment effect estimates
Number of subjects: 0
Study 31018832 — intervention group
Group type: EXPERIMENTAL
Intervention: Piecewise exponential model
Number of subjects: 0
Study 31018832 — intervention group
Group type: EXPERIMENTAL
Intervention: Weibull model
Number of subjects: 0
Study 26914485 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR-assisted procedure
Number of subjects: 103
Study 26914485 — intervention group
Group type: COMPARATOR
Intervention: Standard venipuncture
Number of subjects: 103
Study 26239735 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone and silymarin for 9 months
Number of subjects: 80
Study 26239735 — intervention group
Group type: COMPARATOR
Intervention: Deferiprone and placebo for 9 months
Number of subjects: 80
Study 22709363 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min nurse-led computerized Predict CVD-Diabetes session
Number of subjects: 106
Study 22709363 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 106
Study 20390429 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan (ZD4054) 10 mg or 15 mg
Number of subjects: 312
Study 20390429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 18579392 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 67
Study 18579392 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 67
Study 16352882 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin sealants
Number of subjects: 103
Study 16352882 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer sealants
Number of subjects: 103
Study 12827121 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical local anesthetic (adrenaline 1:1,000, lignocaine 4%, amethocaine 0.5%)
Number of subjects: 161
Study 12827121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (adrenaline 1:1,000 solution)
Number of subjects: 161
Study 10819253 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunts with low working pressure
Number of subjects: 101
Study 10819253 — intervention group
Group type: COMPARATOR
Intervention: Shunts with medium-high working pressure
Number of subjects: 101
Study 8894262 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10 mg, doubled to 40 mg in nonresponders)
Number of subjects: 5609
Study 8894262 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (50 mg, doubled to 200 mg in nonresponders)
Number of subjects: 5609
Study 8894262 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (52 weeks treatment in a volunteer group of 327 patients)
Number of subjects: 5609
Study 8894262 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (52 weeks treatment in a volunteer group of 327 patients)
Number of subjects: 5609
Study 1686701 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 40
Study 1686701 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 40
Study 1686701 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional postoperative methods)
Number of subjects: 40
Study 1686701 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol group (simulated outpatient protocol)
Number of subjects: 40
Study 6144696 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic desensitization
Number of subjects: 30
Study 6144696 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo
Number of subjects: 30
Study 6144696 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 30
Study 30616662 — intervention group
Group type: EXPERIMENTAL
Intervention: MATCH (Modular Approach to Therapy for children with Anxiety, Depression, Trauma and Conduct problems)
Number of subjects: 280
Study 30616662 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 280
Study 29237489 — intervention group
Group type: EXPERIMENTAL
Intervention: High chronic outward force (COF) group (LifeStent Flexstar, Bard Peripheral Vascular Inc.)
Number of subjects: 80
Study 29237489 — intervention group
Group type: COMPARATOR
Intervention: Low chronic outward force (COF) group (Pulsar, Biotronik AG)
Number of subjects: 80
Study 29237489 — intervention group
Group type: EXPERIMENTAL
Intervention: High COF group
Number of subjects: 80
Study 29237489 — intervention group
Group type: COMPARATOR
Intervention: Low COF group
Number of subjects: 80
Study 29237489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 25540062 — intervention group
Group type: EXPERIMENTAL
Intervention: Racing game
Number of subjects: 0
Study 25540062 — intervention group
Group type: COMPARATOR
Intervention: Neutral game
Number of subjects: 0
Study 24838401 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music during electromyography
Number of subjects: 60
Study 24838401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 60
Study 22967497 — intervention group
Group type: EXPERIMENTAL
Intervention: Antazoline administered intravenously in divided doses
Number of subjects: 80
Study 22967497 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously in divided doses
Number of subjects: 80
Study 22967497 — intervention group
Group type: EXPERIMENTAL
Intervention: Antazoline
Number of subjects: 80
Study 22967497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19631852 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect pulp capping treatment; specific details on dosage and duration not available.
Number of subjects: 0
Study 17469162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 158
Study 17469162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 15787181 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalin eye drops
Number of subjects: 72
Study 15787181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 11252048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-minimization analysis (CMA)
Number of subjects: 0
Study 11252048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis (CEA)
Number of subjects: 0
Study 9581139 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical pathway protocol
Number of subjects: 149
Study 9581139 — intervention group
Group type: COMPARATOR
Intervention: Conventional means
Number of subjects: 149
Study 8277200 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated vaccine
Number of subjects: 5210
Study 8277200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted vaccine
Number of subjects: 5210
Study 2470865 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP-BLM
Number of subjects: 45
Study 2470865 — intervention group
Group type: EXPERIMENTAL
Intervention: VBM
Number of subjects: 45
Study 1094034 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzethonium chloride mouthrinse
Number of subjects: 43
Study 1094034 — intervention group
Group type: COMPARATOR
Intervention: Zinc chloride mouthrinse
Number of subjects: 43
Study 1094034 — intervention group
Group type: COMPARATOR
Intervention: Benzethonium chloride combined with zinc chloride mouthrinse
Number of subjects: 43
Study 1094034 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 43
Study 31585174 — intervention group
Group type: EXPERIMENTAL
Intervention: Factorial design trials
Number of subjects: 100
Study 30543761 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, educational advance care planning (ACP) decision aid
Number of subjects: 200
Study 30543761 — intervention group
Group type: COMPARATOR
Intervention: Standard advance care planning (ACP)
Number of subjects: 200
Study 28781129 — intervention group
Group type: EXPERIMENTAL
Intervention: IH oxytocin 400μg
Number of subjects: 16
Study 28781129 — intervention group
Group type: EXPERIMENTAL
Intervention: IH oxytocin (all doses)
Number of subjects: 16
Study 28781129 — intervention group
Group type: COMPARATOR
Intervention: IH placebo
Number of subjects: 16
Study 28781129 — intervention group
Group type: EXPERIMENTAL
Intervention: IH oxytocin
Number of subjects: 16
Study 26011569 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Adenosyl Methionine (SAMe)
Number of subjects: 189
Study 26011569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 26011569 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (selective serotonin reuptake inhibitor)
Number of subjects: 189
Study 23154592 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized, guideline-oriented training program for hypertension management
Number of subjects: 140
Study 23154592 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by primary healthcare providers in control centers
Number of subjects: 140
Study 20738455 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation support
Number of subjects: 6
Study 18053020 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (225 mg, 450 mg, 900 mg)
Number of subjects: 26
Study 18053020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17067505 — intervention group
Group type: EXPERIMENTAL
Intervention: Substances or factors that stimulate or inhibit the reabsorption process of pulmonary edema
Number of subjects: 0
Study 17067505 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpulmonary thermodilution
Number of subjects: 0
Study 12671885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (FOS) 6.6 g, administered 3 times daily after meals
Number of subjects: 9
Study 12671885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10626715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.167 microg x kg(‐1) x hr(‐1) of naloxone (Group 4)
Number of subjects: 80
Study 10626715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 microg x kg(‐1) x hr(‐1) of naloxone (Group 3)
Number of subjects: 80
Study 10626715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.083 microg x kg(‐1) x hr(‐1) of naloxone (Group 2)
Number of subjects: 80
Study 10626715 — intervention group
Group type: COMPARATOR
Intervention: 2 mg epidural morphine bolus with continuous epidural infusion of 4 mg morphine in 100 ml bupivacaine 0.125% (Group 1)
Number of subjects: 80
Study 9174679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen effervescent 400 mg
Number of subjects: 20
Study 9174679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen effervescent 800 mg
Number of subjects: 20
Study 9174679 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen tablets 400 mg
Number of subjects: 20
Study 9174679 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen tablets 800 mg
Number of subjects: 20
Study 9174679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen effervescent
Number of subjects: 20
Study 8254241 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate carotid endarterectomy
Number of subjects: 0
Study 8254241 — intervention group
Group type: COMPARATOR
Intervention: Non-surgery
Number of subjects: 0
Study 3818160 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased smoking involvement
Number of subjects: 0
Study 3818160 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased smoking involvement
Number of subjects: 0
Study 3818160 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant function models
Number of subjects: 0
Study 3818160 — intervention group
Group type: EXPERIMENTAL
Intervention: Variables measured in 1975
Number of subjects: 0
Study 29347904 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training
Number of subjects: 91
Study 29347904 — intervention group
Group type: COMPARATOR
Intervention: Resource activating play group
Number of subjects: 91
Study 30345030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographers reporting high visualization rates (>89%) of normal postmenopausal ovaries
Number of subjects: 349
Study 30345030 — intervention group
Group type: COMPARATOR
Intervention: Expert review of examinations
Number of subjects: 349
Study 26575861 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated pedaling at varying crank powers (20% to 120%)
Number of subjects: 17
Study 26575861 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing pedaling at varying crank powers (20% to 120%)
Number of subjects: 17
Study 23682858 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (60-min exercise class twice a week for 3 months)
Number of subjects: 105
Study 23682858 — intervention group
Group type: COMPARATOR
Intervention: Education group (control)
Number of subjects: 105
Study 23682858 — intervention group
Group type: COMPARATOR
Intervention: Excluded subjects (control)
Number of subjects: 105
Study 23682858 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 105
Study 23682858 — intervention group
Group type: COMPARATOR
Intervention: Excluded participants
Number of subjects: 105
Study 23050472 — intervention group
Group type: EXPERIMENTAL
Intervention: FB1 alone (FX)
Number of subjects: 390
Study 23050472 — intervention group
Group type: EXPERIMENTAL
Intervention: M alone (MX)
Number of subjects: 390
Study 23050472 — intervention group
Group type: EXPERIMENTAL
Intervention: FB1 and M (FM)
Number of subjects: 390
Study 23050472 — intervention group
Group type: COMPARATOR
Intervention: Chick mash alone (CX)
Number of subjects: 390
Study 19594035 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation therapy including joint range of motion, activities of daily living, and restoring muscle strength starting from the 2nd day after surgery.
Number of subjects: 100
Study 19594035 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group did not receive rehabilitation).
Number of subjects: 100
Study 17877855 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience (MS) with reminders of human creatureliness
Number of subjects: 0
Study 17877855 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts about human creatureliness
Number of subjects: 0
Study 17877855 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15667657 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 42
Study 15667657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 15667657 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (subgroup with co-morbid tics)
Number of subjects: 42
Study 11994702 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 18
Study 11994702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9661542 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming intravenous fluids at 42 degrees C
Number of subjects: 38
Study 9661542 — intervention group
Group type: COMPARATOR
Intervention: Room temperature fluids at approximately 21 degrees C (Control)
Number of subjects: 38
Study 7854554 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy according to IOR‐OS/NEO 3 protocol
Number of subjects: 55
Study 2574496 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (non-selective beta blocker)
Number of subjects: 6
Study 2574496 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (beta-1 selective beta blocker)
Number of subjects: 6
Study 2574496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2574496 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6
Study 2574496 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 6
Study 2574496 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 6
Study 237423 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 8165 D (0.4-0.8 mg/kg body weight)
Number of subjects: 50
Study 237423 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 8165 D
Number of subjects: 50
Study 31574127 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-social support by trained school teachers
Number of subjects: 1220
Study 31574127 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psycho-social support)
Number of subjects: 1220
Study 27302563 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB supplementation
Number of subjects: 33
Study 27302563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 25819854 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutonix drug-coated balloon (DCB)
Number of subjects: 476
Study 25819854 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 476
Study 23627460 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (rhIL-10) at various concentrations in rats
Number of subjects: 175
Study 23627460 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (rhIL-10) at low concentrations in humans
Number of subjects: 175
Study 23627460 — intervention group
Group type: COMPARATOR
Intervention: Double deletion of IL-10 and IL-4 genes in KO mice
Number of subjects: 175
Study 23627460 — intervention group
Group type: COMPARATOR
Intervention: Control incisions receiving either placebo or standard care in rats
Number of subjects: 175
Study 23627460 — intervention group
Group type: COMPARATOR
Intervention: Control incisions receiving either standard care or placebo in humans
Number of subjects: 175
Study 21932567 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker metoprolol tartrate
Number of subjects: 45
Study 21932567 — intervention group
Group type: COMPARATOR
Intervention: Standard antianginal therapy (including nitrates, anticoagulants, ACE inhibitors, and statins)
Number of subjects: 45
Study 19304668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (3-month training)
Number of subjects: 39
Study 19304668 — intervention group
Group type: COMPARATOR
Intervention: Non-training group
Number of subjects: 39
Study 16169185 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cognitive-behavioral group treatment (CBGT)
Number of subjects: 26
Study 16169185 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (WG)
Number of subjects: 26
Study 15208485 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 0
Study 15208485 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 0
Study 11738278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin for six months followed by pravastatin and vitamin E for six additional months
Number of subjects: 54
Study 11738278 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E for six months followed by pravastatin and vitamin E for six additional months
Number of subjects: 54
Study 11738278 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin for six months followed by simvastatin and vitamins C and E for six additional months
Number of subjects: 54
Study 10481384 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry (FC)
Number of subjects: 131
Study 8110914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (mean serum level of 0.54 mEq/L)
Number of subjects: 30
Study 8110914 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 8110914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment and Placebo treatment
Number of subjects: 30
Study 3606937 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene hydrochloride 65 mg 8 hourly
Number of subjects: 12
Study 3606937 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 125 mg 8 hourly
Number of subjects: 12
Study 3606937 — intervention group
Group type: COMPARATOR
Intervention: Tolbutamide 500 mg i.v.
Number of subjects: 12
Study 29866131 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) with co-intervention exercise strategies (spine mobilizing and multifidus activating)
Number of subjects: 0
Study 29866131 — intervention group
Group type: COMPARATOR
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 0
Study 29866131 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 0
Study 27831729 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving and communication (CAPS) group
Number of subjects: 132
Study 27831729 — intervention group
Group type: COMPARATOR
Intervention: Internet resources comparison (IRC) group
Number of subjects: 132
Study 23473623 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic capacity (VO2 peak)
Number of subjects: 35
Study 23473623 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 35
Study 23473623 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication use
Number of subjects: 35
Study 23591985 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising + XS
Number of subjects: 26
Study 23591985 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising + STD
Number of subjects: 26
Study 23591985 — intervention group
Group type: COMPARATOR
Intervention: Control + STD
Number of subjects: 26
Study 23591985 — intervention group
Group type: COMPARATOR
Intervention: Control + XS
Number of subjects: 26
Study 20015106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Crisis Team (MCT) intervention
Number of subjects: 120
Study 20015106 — intervention group
Group type: COMPARATOR
Intervention: Standard referral to outpatient mental health clinic (OPC)
Number of subjects: 120
Study 20015106 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MCT and OPC
Number of subjects: 120
Study 19014835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevirimat 200 mg/d for 14 days
Number of subjects: 48
Study 19014835 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg/d on days 1 through 21 and bevirimat 200 mg/d on days 8 through 21
Number of subjects: 48
Study 19014835 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of bevirimat and atazanavir
Number of subjects: 48
Study 19014835 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events
Number of subjects: 48